Keyphrases
Phase II Study
100%
Novel Therapeutics
100%
Hepatitis C
100%
Hepatitis C Virus
100%
Consensus Guidelines
100%
Direct-acting Antivirals
100%
Nave
50%
Patient Preference
50%
Therapeutic Potential
50%
Clinical Setting
50%
Patient Characteristics
50%
Cost Implications
50%
Hepatitis C Virus Infection
50%
Infected Individual
50%
Safety Self-efficacy
50%
New Therapies
50%
Patient-physician
50%
Ribavirin
50%
Pegylated Interferon
50%
Sustained Viral Response
50%
All-phase
50%
Physician Preference
50%
Hepatology
50%
Chronic Hepatitis C Virus Infection
50%
Acute Hepatitis C
50%
Interferon-free Therapy
50%
Simeprevir
50%
Cure Rate
50%
Abstract Presentation
50%
Sofosbuvir
50%
Faldaprevir
50%
Medicine and Dentistry
Hepatitis C
100%
Antiviral Therapy
100%
Hepatitis C Virus
100%
Health Care Cost
66%
Therapeutic Agent
66%
Chronic Hepatitis C
66%
Patient Characteristics
33%
Peginterferon
33%
Ribavirin
33%
Interferon
33%
Hepatology
33%
Faldaprevir
33%
Simeprevir
33%
Sofosbuvir
33%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis C
100%
Hepatitis C Virus
100%
Antiviral Therapy
100%
Chronic Hepatitis C
66%
Interferon
33%
Ribavirin
33%
Peginterferon
33%
Simeprevir
33%
Sofosbuvir
33%
Faldaprevir
33%
Nursing and Health Professions
Practice Guideline
100%
Hepatitis C
100%
Antiviral Therapy
100%
Chronic Hepatitis C
50%
Peginterferon
25%
Simeprevir
25%
Faldaprevir
25%
Interferon
25%
Ribavirin
25%
Sofosbuvir
25%
Sustained Virologic Response
25%